Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, ...

The rate of frailty among patients with multiple sclerosis (MS) ranges from 17% to 66% among ambulatory patients, and frailty ...

Histotripsy is a new, FDA-approved, minimally invasive technique that destroys liver tumors using high-frequency ultrasound ...

Ensartinib offers improved progression-free survival for ALK-positive NSCLC compared with crizotinib, with a median PFS of 25 ...

Rachel Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with ...

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, ...

The 2023 chemotherapy shortage led to a 60% drop in cisplatin use for head and neck cancer, with costly substitutes ...

A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with ...

Researchers study long-term safety of lentiviral gene therapy in primates, finding no evidence of somatic mutations or ...

Based on their findings, the researchers suggest the integration of automated measures to identify interventricular septal ...

Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections ...

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and ...